JP2018538354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538354A5 JP2018538354A5 JP2018533127A JP2018533127A JP2018538354A5 JP 2018538354 A5 JP2018538354 A5 JP 2018538354A5 JP 2018533127 A JP2018533127 A JP 2018533127A JP 2018533127 A JP2018533127 A JP 2018533127A JP 2018538354 A5 JP2018538354 A5 JP 2018538354A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- nhc
- nhnr
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001257 hydrogen Substances 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 150000002431 hydrogen Chemical class 0.000 claims 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010010774 Constipation Diseases 0.000 claims 5
- 208000019693 Lung disease Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000011671 Lacrimal disease Diseases 0.000 claims 1
- 206010023644 Lacrimation increased Diseases 0.000 claims 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000004317 lacrimation Effects 0.000 claims 1
- 230000005980 lung dysfunction Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- QSAKKBGLYQHWAK-UHFFFAOYSA-N COc(ccc(Cc1nnc(NC(Cc2ccc[s]2)=O)[s]1)c1)c1OC Chemical compound COc(ccc(Cc1nnc(NC(Cc2ccc[s]2)=O)[s]1)c1)c1OC QSAKKBGLYQHWAK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387591P | 2015-12-24 | 2015-12-24 | |
| US62/387,591 | 2015-12-24 | ||
| PCT/US2016/068561 WO2017112947A1 (en) | 2015-12-24 | 2016-12-23 | Cftr regulators and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538354A JP2018538354A (ja) | 2018-12-27 |
| JP2018538354A5 true JP2018538354A5 (enExample) | 2020-02-06 |
| JP6894902B2 JP6894902B2 (ja) | 2021-06-30 |
Family
ID=59091233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533127A Active JP6894902B2 (ja) | 2015-12-24 | 2016-12-23 | Ｃｆｔｒ制御因子及びこの使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190031630A1 (enExample) |
| EP (1) | EP3394083B9 (enExample) |
| JP (1) | JP6894902B2 (enExample) |
| KR (1) | KR102723194B1 (enExample) |
| CN (1) | CN108699107B (enExample) |
| AU (2) | AU2016377782B2 (enExample) |
| CL (1) | CL2018001714A1 (enExample) |
| CO (1) | CO2018007239A2 (enExample) |
| ES (1) | ES2901002T3 (enExample) |
| IL (2) | IL299924B2 (enExample) |
| PL (1) | PL3394083T3 (enExample) |
| PT (1) | PT3394083T (enExample) |
| RU (1) | RU2742934C2 (enExample) |
| WO (1) | WO2017112947A1 (enExample) |
| ZA (1) | ZA201804228B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909316T3 (es) | 2015-12-24 | 2022-05-06 | Univ California | Reguladores de CFTR y métodos de uso de los mismos |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
| FR3096890B1 (fr) * | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| US20220071549A1 (en) * | 2020-09-08 | 2022-03-10 | The Regents Of The University Of California | Apparatus, systems and methods of use for ocular surface potential difference measurement |
| PY2193067A (es) | 2020-10-23 | 2022-06-20 | Ildong Pharmaceutical Co Ltd | Compuestos moduladores del cftr, composiciones y usos de estos |
| CN113527225B (zh) * | 2021-07-15 | 2022-11-18 | 南昌大学 | 一种丙烯酰噻二唑衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9815785A (pt) | 1998-03-31 | 2000-12-05 | Warner Lambert Co | Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina |
| BR0314943A (pt) * | 2002-09-30 | 2005-08-02 | Univ California | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes |
| US7977322B2 (en) * | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| BRPI0507278A (pt) * | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| US20090105240A1 (en) * | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| ES2548583T3 (es) | 2008-03-05 | 2015-10-19 | Merck Patent Gmbh | Derivados de quinoxalinona como estimuladores de la secreción de insulina, métodos para su obtención y su uso para el tratamiento de la diabetes |
| US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010073011A2 (en) * | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| TWI450891B (zh) * | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| CA2942386A1 (en) * | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| EP3157917B1 (en) * | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
-
2016
- 2016-12-23 RU RU2018126959A patent/RU2742934C2/ru active
- 2016-12-23 IL IL299924A patent/IL299924B2/en unknown
- 2016-12-23 PT PT168801561T patent/PT3394083T/pt unknown
- 2016-12-23 ES ES16880156T patent/ES2901002T3/es active Active
- 2016-12-23 US US16/016,300 patent/US20190031630A1/en not_active Abandoned
- 2016-12-23 WO PCT/US2016/068561 patent/WO2017112947A1/en not_active Ceased
- 2016-12-23 JP JP2018533127A patent/JP6894902B2/ja active Active
- 2016-12-23 AU AU2016377782A patent/AU2016377782B2/en active Active
- 2016-12-23 CN CN201680082474.2A patent/CN108699107B/zh active Active
- 2016-12-23 PL PL16880156T patent/PL3394083T3/pl unknown
- 2016-12-23 EP EP16880156.1A patent/EP3394083B9/en active Active
- 2016-12-23 KR KR1020187021185A patent/KR102723194B1/ko active Active
-
2018
- 2018-06-21 IL IL260210A patent/IL260210B2/en unknown
- 2018-06-21 CL CL2018001714A patent/CL2018001714A1/es unknown
- 2018-06-22 ZA ZA2018/04228A patent/ZA201804228B/en unknown
- 2018-07-11 CO CONC2018/0007239A patent/CO2018007239A2/es unknown
-
2019
- 2019-10-28 US US16/666,278 patent/US11192869B2/en active Active
-
2021
- 2021-10-26 AU AU2021257948A patent/AU2021257948B2/en active Active